BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33985932)

  • 1. Progression to Symptomatic Multiple Myeloma Predicted by Texture Analysis-Derived Parameters in Patients Without Focal Disease at
    Ripani D; Caldarella C; Za T; Rossi E; De Stefano V; Giordano A
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):536-544. PubMed ID: 33985932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma.
    Amini B; Nakache YN; Nardo L; Manasanch EE; Sun J; Lenchik L; Boutin RD
    Skeletal Radiol; 2021 Jan; 50(1):79-85. PubMed ID: 32621061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of
    Ou X; Wang J; Zhou R; Zhu S; Pang F; Zhou Y; Tian R; Ma X
    Contrast Media Mol Imaging; 2019; 2019():4507694. PubMed ID: 30930700
    [No Abstract]   [Full Text] [Related]  

  • 5. Can pretreatment
    Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
    Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
    J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
    Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
    Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow segmentation and radiomics analysis of [
    Milara E; Gómez-Grande A; Tomás-Soler S; Seiffert AP; Alonso R; Gómez EJ; Martínez-López J; Sánchez-González P
    Comput Methods Programs Biomed; 2022 Oct; 225():107083. PubMed ID: 36044803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
    Zamagni E; Nanni C; Gay F; Pezzi A; Patriarca F; Bellò M; Rambaldi I; Tacchetti P; Hillengass J; Gamberi B; Pantani L; Magarotto V; Versari A; Offidani M; Zannetti B; Carobolante F; Balma M; Musto P; Rensi M; Mancuso K; Dimitrakopoulou-Strauss A; Chauviè S; Rocchi S; Fard N; Marzocchi G; Storto G; Ghedini P; Palumbo A; Fanti S; Cavo M
    Leukemia; 2016 Feb; 30(2):417-22. PubMed ID: 26490489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
    Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
    Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
    Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
    Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
    Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
    Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
    Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
    Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
    J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of [
    Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Pellegrino S; Catalano L; Pane F; Del Vecchio S; Pace L
    Ann Hematol; 2020 Jan; 99(1):127-135. PubMed ID: 31776725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.